ESR1 and breast cancer: The ER (+) and/or PR (+) and HER2 (−) groups account for two-thirds of all BC (Ignatiadis and Sotiriou, 2013), which is sensitive to endocrine therapy and has a better prognosis than HER2-positive or triple-negative BC (TNBC).